These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 500231)

  • 1. Heterotoxicity of human serum. IV. Role of the alternative complement pathway and natural antibody in the lethal toxicity of human serum for mice.
    Rozenfarb E; Eidinger D
    Int Arch Allergy Appl Immunol; 1979; 60(4):414-26. PubMed ID: 500231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activation of the alternative complement pathway by fetal calf serum and mouse thymocytes.
    Eisenberg RA; Theofilopoulos AN; Dixon FJ
    J Immunol; 1979 May; 122(5):2045-51. PubMed ID: 87451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the alternative pathway of human complement by haemoglobin.
    Wilson WA; Thomas EJ
    Clin Exp Immunol; 1979 Apr; 36(1):140-4. PubMed ID: 111881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative complement pathway by normal and transformed cells in homologous and heterologous sera.
    McConnell I; Gorman NT; Raniwalla J; Powell P
    Eur J Immunol; 1981 Feb; 11(2):126-32. PubMed ID: 6260511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages.
    Mosser DM; Edelson PJ
    J Immunol; 1984 Mar; 132(3):1501-5. PubMed ID: 6363545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysis of horse red blood cells mediated by antibody-independent activation of the alternative pathway of chicken complement.
    Ohta H; Yoshikawa Y; Kai C; Yamanouchi K; Okada H
    Immunology; 1984 Jul; 52(3):437-44. PubMed ID: 6430791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternate complement pathway activation by recluse spider venom.
    Kurpiewski G; Campbell BJ; Forrester LJ; Barrett JT
    Int J Tissue React; 1981 Mar; 3(1):39-45. PubMed ID: 7287056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.
    Okada N; Harada R; Fujita T; Okada H
    J Immunol; 1989 Oct; 143(7):2262-6. PubMed ID: 2476502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
    Ekdahl KN; Nilsson B
    J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):7-10. PubMed ID: 6778918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase.
    Moore FD; Austen KF; Fearon DT
    J Immunol; 1982 Mar; 128(3):1302-6. PubMed ID: 6915957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of decomplementation on mercuric chloride-induced glomerulonephritis in Brown-Norway rats.
    Capron M; Bascou C; Vial MC; Grossetete J; Hinglais N; Girard JF; Druet P
    Clin Exp Immunol; 1982 Sep; 49(3):611-7. PubMed ID: 6216993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Concentration-functional interrelationships in the human alternative complement activation pathway].
    Galebskaia LV; Shcherbak IG; Bel'tiukov PP; Riumina EV; Solovtsova IL
    Biokhimiia; 1993 Nov; 58(11):1796-800. PubMed ID: 8268316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the alternative pathway of complement by human peripheral nerve myelin.
    Koski CL; Vanguri P; Shin ML
    J Immunol; 1985 Mar; 134(3):1810-4. PubMed ID: 2578522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b.
    Moore FD; Fearon DT; Austen KF
    J Immunol; 1981 May; 126(5):1805-9. PubMed ID: 6908606
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterotoxicity of human serum. V. Development of hematological abnormalities in mice suggestive of disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
    Rozenfarb E; Eidinger D
    Int Arch Allergy Appl Immunol; 1979; 60(4):427-40. PubMed ID: 574127
    [No Abstract]   [Full Text] [Related]  

  • 17. Susceptibility of Giardia lamblia trophozoites to the lethal effect of human serum.
    Hill DR; Burge JJ; Pearson RD
    J Immunol; 1984 Apr; 132(4):2046-52. PubMed ID: 6699407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum.
    Schreiber AD; Frank MM
    J Clin Invest; 1972 Mar; 51(3):583-9. PubMed ID: 4622104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model.
    Wagner E; Platt JL; Howell DN; Marsh HC; Frank MM
    J Immunol; 1999 Sep; 163(6):3549-58. PubMed ID: 10477630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.